-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Tianjin Medical Insurance Bureau issued the "Notice on Implementing the Fifth Batch of Nationally Organized Drug Centralized Procurement and Use", clarifying that from September 20, the city will implement the fifth batch of 61 reduced-price drugs purchased by the country
.
61 types of reduced-price drugs involve the treatment of common diseases such as hypertension, anti-allergic, anti-infection, coronary heart disease, diabetes, gastrointestinal diseases, and chronic diseases, as well as major diseases such as lung cancer, breast cancer, and colorectal cancer
.
It is reported that this batch of medicines has dropped by an average of 56%.
According to the statistics of contracted purchases in Tianjin, it is estimated that 265 million yuan of medicine purchase costs can be saved each year, which will effectively reduce the burden of medication for patients
.
According to the detailed list of drugs, the companies involved include local pharmaceutical companies such as Hengrui, Hausen, Kelun Pharmaceutical, Chia Tai Tianqing, and Yangtze River, as well as foreign companies such as Tianjin Tanabe Pharmaceutical and GSK
.
Among them, Tianjin Tanabe Pharmaceutical’s 10mg benzenesulfonylbepotastine tablets, the selected price is only 7.
5 yuan, this product is suitable for urticaria, pruritic skin diseases, dermatitis and eczema and other skin-related allergic diseases and allergic rhinitis.
The exact curative effect; the selected price of GSK's dutasteride soft capsule 0.
5mg is 30.
95 yuan/box.
This product belongs to the urinary system drug and can be used for patients with benign prostatic hyperplasia (BPH) with moderate to severe symptoms to reduce acute urinary retention (AUR) and the risks of surgery
.
The product was approved to enter the domestic market in April 2011, and currently only the original research manufacturer GSK is selling it.
In 2018, global sales were 572 million pounds
.
However, GSK is currently facing the impact of generic drugs
.
The industry believes that GSK will take the initiative to lower prices and concentrate on sourcing, or in order to maintain the previous market, it will not hesitate to supply at a lower price
.
In addition to the good news of the price reduction of medicines, the Tianjin Pharmaceutical Purchasing Center recently issued the "Notice on Carrying out the Linkage Procurement of Coronary Drug Balloons and Pacemaker Medical Consumables in the Beijing-Tianjin-Hebei "3+N" Alliance" , The Beijing-Tianjin-Hebei medical security department formed a "3+N" alliance with the voluntarily joined regions such as Heiji, Liao, Mengjin, Shandong, Henan, Sichuan, Guizhou and Tibet, and launched the Beijing-Tianjin-Hebei "3+N" alliance for coronary drug balloons and pacing Procurement project of equipment medical consumables with quantity linkage
.
Among them, the procurement entities in Beijing area have already implemented the results of the selection of balloons for coronary drugs and will no longer participate; the procurement entities in Shandong only participate in the implementation of the results of the selection of balloons for coronary drugs; the procurement entities in Shanxi, Henan and Guizhou only participate in the implementation of pacemakers The result of the selection in the class
.
The purchased products are coronary drug balloons and pacemakers.
The purchase agreement is signed for one year for the first time
.
In principle, the purchase amount for renewed purchase agreements is determined on a pro rata basis .
In addition, artificial joint medical consumables products have been purchased in Tianjin on September 14th.
The centralized procurement of artificial joints includes primary replacement artificial total hip joints and primary replacement artificial knee joints.
The procurement cycle for the quantity of artificial joints is 2 years
.
According to the results of the proposed selection, a total of 44 companies were selected.
The average price of hip joints of the proposed selection decreased from 35,000 yuan to about 7,000 yuan, and the average price of knee joints decreased from 32,000 yuan to about 5,000 yuan, an average price reduction of 82%.
Greatly reduce the cost burden
.
It is reported that in the next step, the Tianjin medical insurance department will effectively perform the "joint procurement" responsibilities assigned by the state, and simultaneously implement the China Medical Insurance Medical Consumables Registration System (artificial joints) to retrospectively monitor the production, circulation, use, and overall conditions of patients with artificial joints.
, To achieve full-process and full-cycle closed-loop management to ensure the smooth implementation of the selected results of the national organization of centralized procurement of artificial joints in the country
.
.
61 types of reduced-price drugs involve the treatment of common diseases such as hypertension, anti-allergic, anti-infection, coronary heart disease, diabetes, gastrointestinal diseases, and chronic diseases, as well as major diseases such as lung cancer, breast cancer, and colorectal cancer
.
It is reported that this batch of medicines has dropped by an average of 56%.
According to the statistics of contracted purchases in Tianjin, it is estimated that 265 million yuan of medicine purchase costs can be saved each year, which will effectively reduce the burden of medication for patients
.
According to the detailed list of drugs, the companies involved include local pharmaceutical companies such as Hengrui, Hausen, Kelun Pharmaceutical, Chia Tai Tianqing, and Yangtze River, as well as foreign companies such as Tianjin Tanabe Pharmaceutical and GSK
.
Among them, Tianjin Tanabe Pharmaceutical’s 10mg benzenesulfonylbepotastine tablets, the selected price is only 7.
5 yuan, this product is suitable for urticaria, pruritic skin diseases, dermatitis and eczema and other skin-related allergic diseases and allergic rhinitis.
The exact curative effect; the selected price of GSK's dutasteride soft capsule 0.
5mg is 30.
95 yuan/box.
This product belongs to the urinary system drug and can be used for patients with benign prostatic hyperplasia (BPH) with moderate to severe symptoms to reduce acute urinary retention (AUR) and the risks of surgery
.
The product was approved to enter the domestic market in April 2011, and currently only the original research manufacturer GSK is selling it.
In 2018, global sales were 572 million pounds
.
However, GSK is currently facing the impact of generic drugs
.
The industry believes that GSK will take the initiative to lower prices and concentrate on sourcing, or in order to maintain the previous market, it will not hesitate to supply at a lower price
.
In addition to the good news of the price reduction of medicines, the Tianjin Pharmaceutical Purchasing Center recently issued the "Notice on Carrying out the Linkage Procurement of Coronary Drug Balloons and Pacemaker Medical Consumables in the Beijing-Tianjin-Hebei "3+N" Alliance" , The Beijing-Tianjin-Hebei medical security department formed a "3+N" alliance with the voluntarily joined regions such as Heiji, Liao, Mengjin, Shandong, Henan, Sichuan, Guizhou and Tibet, and launched the Beijing-Tianjin-Hebei "3+N" alliance for coronary drug balloons and pacing Procurement project of equipment medical consumables with quantity linkage
.
Among them, the procurement entities in Beijing area have already implemented the results of the selection of balloons for coronary drugs and will no longer participate; the procurement entities in Shandong only participate in the implementation of the results of the selection of balloons for coronary drugs; the procurement entities in Shanxi, Henan and Guizhou only participate in the implementation of pacemakers The result of the selection in the class
.
The purchased products are coronary drug balloons and pacemakers.
The purchase agreement is signed for one year for the first time
.
In principle, the purchase amount for renewed purchase agreements is determined on a pro rata basis .
In addition, artificial joint medical consumables products have been purchased in Tianjin on September 14th.
The centralized procurement of artificial joints includes primary replacement artificial total hip joints and primary replacement artificial knee joints.
The procurement cycle for the quantity of artificial joints is 2 years
.
According to the results of the proposed selection, a total of 44 companies were selected.
The average price of hip joints of the proposed selection decreased from 35,000 yuan to about 7,000 yuan, and the average price of knee joints decreased from 32,000 yuan to about 5,000 yuan, an average price reduction of 82%.
Greatly reduce the cost burden
.
It is reported that in the next step, the Tianjin medical insurance department will effectively perform the "joint procurement" responsibilities assigned by the state, and simultaneously implement the China Medical Insurance Medical Consumables Registration System (artificial joints) to retrospectively monitor the production, circulation, use, and overall conditions of patients with artificial joints.
, To achieve full-process and full-cycle closed-loop management to ensure the smooth implementation of the selected results of the national organization of centralized procurement of artificial joints in the country
.
